Antibodies against HPV16E6 oncoprotein in the Swiss HIV Cohort Study: kinetics and anal cancer risk prediction

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Chronic PainComplex Regional Pain Syndrome (CRPS)

Coronary Artery Disease-associated and Longevity-associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living with HIV: The Swiss HIV Cohort Study

Clin Infect Dis

Schoepf IC, Thorball CW, Ledergerber B, Engel T, Raffenberg M, Kootstra NA, Reiss P, Hasse B, Marzolini C, Thurnheer C, Seneghini M, Bernasconi E, Cavassini M, Buvelot H, Kouyos R, Günthard HF, Fellay J, Tarr PE, , for the Swiss HIV Cohort Study.

doi: 10.1093/cid/ciab521

HIV / AIDS

Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017

HIV Med.

Hampel B, Kusejko K, Kouyos RD, Böni J, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Nicca D, Schmidt AJ, Nguyen H, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Braun DL, Fehr J, Swiss HIV Cohort Study group.

doi: 10.1111/hiv.12821.

HIV / AIDS

Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors

Clin Infect Dis.

Deutschmann E, Bucher HC, Jaeckel S, Gibbons S, McAllister K, Scherrer AU, Braun DL, Cavassini M, Hachfeld A, Calmy A, Battegay M, Cipriani M, Elzi L, Young J, Lopez-Centeno B, Berenguer J, Khoo S, Moffa G, Marzolini C, Swiss HIV Cohort Study.

doi: 10.1093/cid/ciaa918.

HIV / AIDS

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study

Virus Evol.

Kusejko K, Kadelka C, Marzel A, Battegay M, Bernasconi E, Calmy A, Cavassini M, Hoffmann M, Böni J, Yerly S, Klimkait T, Perreau M, Rauch A, Günthard HF, Kouyos RD, Swiss HIV Cohort Study

doi: 10.1093/ve/vey024.

HIV / AIDS

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study

Antivir Ther.

Young J, Scherrer AU, Calmy A, Tarr PE, Bernasconi E, Cavassini M, Hachfeld A, Vernazza P, Günthard HF, Bucher HC, Swiss HIV Cohort Study

doi: 10.3851/IMP3310.

HIV / AIDSDrug Resistance

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients

Clin Infect Dis.

Abela IA, Scherrer AU, Böni J, Yerly S, Klimkait T, Perreau M, Hirsch HH, Furrer H, Calmy A, Schmid P, Cavassini M, Bernasconi E, Günthard HF; Swiss HIV Cohort Study

doi: 10.1093/cid/ciz178.

HIV / AIDS

Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018

Antivir Ther.

Kusejko K, Marzel A, Nguyen H, Chaudron SE, Bachmann N, Weber R, Bruggmann P, Roth JA, Bernasconi E, Calmy A, Cavassini M, Bregenzer A, Böni J, Yerly S, Klimkait T, Perreau M, Walti LN, Günthard HF, Kouyos RD, Swiss HIV Cohort Study.

doi: 10.3851/IMP3347.

HIV / AIDS

Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study

AIDS.

Courlet P, Stader F, Guidi M, Saldanha SA, Stoeckle M, Cavassini M, Battegay M, Buclin T, Decosterd LA, Marzolini C, Swiss HIV Cohort Study.

doi: 10.1097/QAD.

Related content

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Coronary Artery Disease-associated and Longevity-associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living with HIV: The Swiss HIV Cohort Study

Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017

Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients

Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018

Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study